Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination

Area of Science:

• Immunology
• Dermatology
• Vaccinology

Background:

• COVID-19 vaccination significantly reduces severe disease and mortality.
• Safety data for COVID-19 vaccines in patients with autoimmune skin conditions remain limited.

Purpose of the Study:

• To assess the incidence of autoimmune skin disease exacerbation post-COVID-19 vaccination.
• To identify factors associated with vaccine-related disease flares in this population.

Main Methods:

• A chart review was conducted on patients with autoimmune skin disease.
• Standardized questionnaires collected data on vaccination status, autoimmune symptoms, and timing of onset.
• Chi-square and Fisher's exact tests were used for analysis.

Main Results:

• 14.8% of fully vaccinated patients reported worsening autoimmune symptoms.
• Dermatomyositis patients (22.7%) were more likely to experience flares than lupus erythematosus patients (8.6%).
• Moderna vaccine recipients showed a trend towards increased symptom exacerbation compared to Pfizer-BioNTech recipients.

Conclusions:

• Dermatomyositis patients experienced higher rates of autoimmune symptom exacerbation post-vaccination compared to lupus erythematosus patients.
• Despite potential flares, COVID-19 vaccination is recommended for most individuals with autoimmune skin disease due to the risks of SARS-CoV-2 infection.